Introduction
This analysis examines the historical and forecast performance for Biogen Idec in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits
Strategic insight into the prospects for Biogen Idec over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered
This analysis examines the historical and forecast performance for Biogen Idec in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits
- Gain insight into Biogen Idec's strategic outlook across the next 6 years
- Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
Strategic insight into the prospects for Biogen Idec over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered
- Benchmark Biogen Idec's performance against key rivals in the prescription pharmaceutical sector
- See how the launch of company's multiple sclerosis portfolio is in transition as oral treatments become available
Executive Summary
Key findings
Prescription pharmaceutical sales and growth rate performance, 2003–15
Financial performance, 2003–15
Biogen Idec: PharmaVitae forecasts at a glance
Strategic insight
Biogen Idec’s key multiple sclerosis franchise in transition
Biogen MS franchise, with a high dependency on new launches, will remain central to the company’s future performance, as sales growth of Rituxan slows
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
ABOUT THIS PROFILE
PharmaVitae Explorer database
Chapter structure
Quarterly news update
Company introduction
Company sales
Company financials
Key products and competitors
Data sourcing
Analyst consensus
QUARTERLY NEWS UPDATE
Latest quarterly sales
Latest comment
Q1 2010
Q4 2009
Q3 2009
Q2 2009
Q1 2009
Latest prescription pharma product news
Q2 2010
Q1 2010
Q4 2009
Q3 2009
Q2 2009
Q1 2009
Latest corporate news
Q1 2010
Q4 2009
Q3 2009
Q2 2009
Q1 2009
Future product milestones
COMPANY INTRODUCTION
Key findings
Background
M&A history
Conforma Therapeutics
Fumapharm AG
Syntonix
Biogen Idec loses out to Abbott for Facet
Current corporate structure
Biopharmaceuticals
COMPANY SALES
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2003–15
Product analysis
Product analysis, 2003–09
Product analysis, 2009–15
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
Explanation of launch/core/expiry analysis
Launch analysis, 2009–15
Core analysis, 2009–15
Expiry analysis, 2009–15
Launch/core/expiry configuration, 2009–15
Molecule type analysis
Externalization analysis
COMPANY FINANCIALS
Key findings
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003–09
Operating costs and profit analysis
Operating costs and profit analysis, 2003–09
Operating cost ratio and profit margin analysis, 2003–09
Operating cost ratio and profit margin analysis, 2009–15
Operating costs and profit analysis, 2009–15
KEY PRODUCTS AND COMPETITORS
Key findings
Overview
Central nervous system
Avonex
Tysabri
Panaclar
Oncology
Rituxan royalties
APPENDIX
References
Abbreviations
About Datamonitor
Key findings
Prescription pharmaceutical sales and growth rate performance, 2003–15
Financial performance, 2003–15
Biogen Idec: PharmaVitae forecasts at a glance
Strategic insight
Biogen Idec’s key multiple sclerosis franchise in transition
Biogen MS franchise, with a high dependency on new launches, will remain central to the company’s future performance, as sales growth of Rituxan slows
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
ABOUT THIS PROFILE
PharmaVitae Explorer database
Chapter structure
Quarterly news update
Company introduction
Company sales
Company financials
Key products and competitors
Data sourcing
Analyst consensus
QUARTERLY NEWS UPDATE
Latest quarterly sales
Latest comment
Q1 2010
Q4 2009
Q3 2009
Q2 2009
Q1 2009
Latest prescription pharma product news
Q2 2010
Q1 2010
Q4 2009
Q3 2009
Q2 2009
Q1 2009
Latest corporate news
Q1 2010
Q4 2009
Q3 2009
Q2 2009
Q1 2009
Future product milestones
COMPANY INTRODUCTION
Key findings
Background
M&A history
Conforma Therapeutics
Fumapharm AG
Syntonix
Biogen Idec loses out to Abbott for Facet
Current corporate structure
Biopharmaceuticals
COMPANY SALES
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2003–15
Product analysis
Product analysis, 2003–09
Product analysis, 2009–15
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
Explanation of launch/core/expiry analysis
Launch analysis, 2009–15
Core analysis, 2009–15
Expiry analysis, 2009–15
Launch/core/expiry configuration, 2009–15
Molecule type analysis
Externalization analysis
COMPANY FINANCIALS
Key findings
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003–09
Operating costs and profit analysis
Operating costs and profit analysis, 2003–09
Operating cost ratio and profit margin analysis, 2003–09
Operating cost ratio and profit margin analysis, 2009–15
Operating costs and profit analysis, 2009–15
KEY PRODUCTS AND COMPETITORS
Key findings
Overview
Central nervous system
Avonex
Tysabri
Panaclar
Oncology
Rituxan royalties
APPENDIX
References
Abbreviations
About Datamonitor